News - Onyx Pharmaceuticals, carfilzomib

Filter

Popular Filters

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma

15-05-2013

US and European hematological oncologists surveyed by health care advisory firm Decision Resources indicate…

carfilzomibEuropeKyprolisMarkets & MarketingNorth AmericaOncologyOno PharmaceuticalOnyx PharmaceuticalsPharmaceuticalpomalidomide

Batch of mixed opinions from FDA advisory panels

21-06-2012

Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of…

carfilzomibKyprolisMerck & CoNorth AmericaOncologyOnyx PharmaceuticalsPfizerPharmaceuticalPneumovaxPrevnarRegulationSanofisemuloparinVaccines

Onyx Pharma links with Texas MD Anderson Cancer Center on research

05-06-2012

US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center…

BiotechnologycarfilzomibOncologyOnyx PharmaceuticalsoprozomibResearch

Onyx falls as FDA says no priority review for cancer drug

13-12-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) saw its shares fall 7.1% to $37.76 in early trading…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Onyx Pharma files NDA for multiple myeloma drug carfilzomib

29-09-2011

California, USA-based Onyx Pharmaceuticals (Nasdaq: ONXX) says it has completed the New Drug Application…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Back to top